Oral teicoplanin for successful treatment of severe refractory clostridium difficile infection

Journal of Infection in Developing Countries

Volumn 9, Issue 10, 2015, Pages 1062-1067

  Popovic, Natasa ^a   Korac, Milos ^a,b   Nesic, Zorica ^b,c   Milosevic, Branko ^a,b   Urosevic, Aleksandar ^a,b   Jevtovic, Djordje ^a,b   Pelemis, Mijomir ^a,b   Delic, Dragan ^a,b   Prostran, Milica ^b,c   Milosevic, Ivana ^a,b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c Clinic of Emergency and Clinical Toxicology and Pharmacology   (Serbia)

Author keywords

Clostridium difficile; Oral teicoplanin; Recurrence; Refractory pseudomembranous colitis

Indexed keywords

METRONIDAZOLE; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL TENDERNESS; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; ASCITES; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; DIARRHEA; DISEASE SEVERITY; FEMALE; FEVER; HUMAN; HYPOTENSION; ILEUS; MAJOR CLINICAL STUDY; MALE; PLEURA EFFUSION; PROSPECTIVE STUDY; RECURRENT DISEASE; RESPIRATORY FAILURE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PEPTOCLOSTRIDIUM DIFFICILE; SERBIA; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DIARRHEA; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; RECURRENCE; SERBIA; TEICOPLANIN; TREATMENT OUTCOME;

EID: 84945540326     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.6335     Document Type: Article

References (14)

1. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun MS (2013) Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108: 478-498.
2. Kuijper EJ, Wilcox MH (2008). Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection? Clin Infect Dis 47: 63-65.
3. Herpers BL, Vlaminckx B, Burkhardt O, Blom H, Biemond-Moeniralam HS, Hornef M, Welte T, Kuijper EJ (2009) Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 48: 1732-1735.
4. McPherson S, Rees CJ, Ellis R, Soo S, Panter SJ (2006) Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhoea. Dis Colon Rectum 49: 640-645.
5. Public Health England (2013) Updated guidance on the management and treatment of Clostridium difficile infection. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/321891/Clostridium_difficile_management_and_treatment.pdf. Last accessed April 2, 2015
6. Kim PK, Huh HC, Cohen HW, Feinberg EJ, Ahmad S, Coyle C, Teperman S, Boothe H (2013) Intracolonic vancomycin for severe Clostridium difficile colitis. Surg Infect (Larchmt) 14: 532-539.
7. Wenisch C, Parschalk B, Hasenhündl M, Hirschl AM, Graninger W (1996) Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhoea. Clin Infect Dis 22: 813-818.
8. De Lalla F, Nicolin R, Rinaldi E, Scarpellini P, Rigoli R, Manfrin V, Tramarin A (1992) Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhoea. Antimicrob Agents Chemother 36: 2192-2196.
9. Debast SB, Bauer MP, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases Collaborators (13) (2014) European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20 Suppl 2: 1-26.
10. Declaration of Helsinki Recommendation Guiding Physicians in Biomedical Research involving human subjects (1997) JAMA 277: 925–926
11. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK, OPT-80-003 Clinical Study Group (2011) Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364: 422–431.
12. Peláez T, Alcalá L, Alonso R, Rodríguez-Créixems M, García-Lechuz JM, Bouza E (2002) Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 46: 1647-1650.
13. Pantosti A, Luzzi I, Cardines R, Gianfrilli (1985) Comparison of the in vitro activities of teicoplanin and vancomycin against Clostridium difficile and their interactions with cholestyramine. Antimicrob Agents Chemother 28: 847-848.
14. Gerding D, Muto C, Owens R Jr (2008). Treatment of Clostridium difficile infection. Clin Infect Dis 46: S32-S42.